USANA Health Sciences (USNA) Tops Q3 EPS by 19c, Updates FY Guidance

USANA Health Sciences (NYSE: USNA) reported Q3 EPS of $1.44, $0.19 better than the analyst estimate of $1.25. Revenue for the quarter came in at $298.5 million versus the consensus estimate of $277.26 million.

GUIDANCE:

USANA Health Sciences sees FY2020 EPS of $5.15-$5.45, versus the consensus of $5.18. USANA Health Sciences sees FY2020 revenue of $1.09-1.115 billion, versus the consensus of $1.08 billion.

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Prenetics Global (PRE) Tops Q2 EPS by 18c
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance